LORATADINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H23ClN2O2
Molecular Weight	382.883
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)N1CCC(CC1)=C2C3=CC=C(Cl)C=C3CCC4=C2N=CC=C4

InChI

InChIKey=JCCNYMKQOSZNPW-UHFFFAOYSA-N

InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

HIDE SMILES / InChI

Molecular Formula	C22H23ClN2O2
Molecular Weight	382.883
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021952Orig1s012lbl.pdf

Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 316 Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7581058	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
Upper respiratory allergies 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021952Orig1s012lbl.pdf	Primary		Approved 8583	CLARITIN Approved Use Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •itchy, watery eyes •sneezing •itching of the nose or throat Launch Date 1993

C_max

Value	Dose	Analyte	Population
10.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
34.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
96 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
56.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
14.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/	40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	LORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021165s014lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2572617/	unhealthy, 29 Health Status: unhealthy Age Group: 29 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2572617/	Other AEs: Somnolence, Headache... Other AEs: Somnolence (10%) Headache (9%) Fatigue (5%) Dry mouth (4%) Sources: https://pubmed.ncbi.nlm.nih.gov/2572617/
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-641S007_Loratadine_medr.pdf	unhealthy, 3.6 Health Status: unhealthy Age Group: 3.6 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-641S007_Loratadine_medr.pdf	Other AEs: Fatigue, Fever... Other AEs: Fatigue (2%) Fever (7%) Headache (5%) Influenza-like symptoms (2%) Constipation (2%) Diarrhea (3%) Dyspepsia (2%) Loose stools (2%) Stomatitis (2%) Tooth disorder (2%) Vomiting (5%) Earache (2%) Drowsiness (7%) Infection viral (2%) Allergic rhinitis (2%) Coughing (3%) Epistaxis (3%) Pharyngitis (3%) Rash (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-641S007_Loratadine_medr.pdf
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10929922/	unhealthy, 35.3 Health Status: unhealthy Age Group: 35.3 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/10929922/	Other AEs: Headache... Other AEs: Headache (4.2%) Sources: https://pubmed.ncbi.nlm.nih.gov/10929922/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	substrate 1193 inhibitor 2438 activator 23	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 2057 CYP1A2 2153 CYP2C8 1057 P-gp 1741	CYP1A1 389 CYP2C19 1119 CYP1A2 1197 CYP2B6 776 CYP2C8 810 CYP3A5 446 P-gp 2052	CYP3A1/2 3 CYP2B1 26 CYP2B2 15 CYP1A1 151

Drug as perpetrator

Target	Modality	Activity
CYP1A1 272	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11502723/	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10597902/ Page: 11.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11502723/	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11502723/	yes [IC50 0.61 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11502723/	yes [IC50 0.76 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/11454724/	yes [IC50 11 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/ Page: 6.0	yes [IC50 3.36 uM]
CYP2B1 41	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0	yes
CYP2B2 16	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0	yes
CYP2C9 2497	activator 342 Sources: https://pubmed.ncbi.nlm.nih.gov/10597902/ Page: 1,8	yes
CYP3A1/2 4	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf#page=1 Page: 1.0	major	yes (co-administration study) Comment: Coadministration with either ketoconazole, erythromycin (both CYP3A4 inhibitors) increased AUC of drug by 307%, 40%, respectively; coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf#page=1 Page: 1.0
CYP1A1 389	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2C8 810	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP3A5 446	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19702548/	minor
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf#page=1 Page: 1.0	minor	yes (co-administration study) Comment: coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20641s7lbl.pdf#page=1 Page: 1.0
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12584158/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/10604956/

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	NO15960	https://www.001chemical.com/chem/79794-75-5
3B Scientific (Wuhan) Corp	3B1-00337	http://www.3bsc.com/index/pro_info.php?id=20549
3B Scientific (Wuhan) Corp	3B2-0771	http://www.3bsc.com/index/pro_info.php?id=20127
AA Blocks	AA00ICZV	https://www.aablocks.com/goods/Goods/detail?id=AA00ICZV
Aaron Chemicals	AR00IDRN	http://www.aaronchem.com/79794-75-5
abcr GmbH	AB261650	http://www.abcr.com/shop/en/AB261650
AbMole Bioscience	M5752	http://www.abmole.com/products/loratadine.html
Accela ChemBio Inc	SY052751	http://www.accelachem.com/cn/search.html?keyword=SY052751&attname=GoodsCode
Achemo Scientific Limited	AC-14832	http://www.achemo.com/product_view.asp?ID=4722
Achemo Scientific Limited	AC-74979	http://www.achemo.com/search/?Keyword= 79794-75-5
Achemtek	0104-001717	http://www.achemtek.com/79794-75-5
Acorn PharmaTech	ACN-048230	http://www.acornpharmatech.com/
Adooq BioScience	A10538	https://www.adooq.com/loratadine.html
AEchem Scientific Corp., USA	AE1-019802	http://www.aechemsc.com/info_products/AE1-019802.php
AHH Chemical co.,ltd	API-1744	http://www.ahhchemical.com/product/API-1744.html
AK Scientific, Inc. (AKSCI)	71291	http://www.aksci.com/item_detail.php?cat=71291
AK Scientific, Inc. (AKSCI)	HTS028367	http://www.aksci.com/item_detail.php?cat=HTS028367
AK Scientific, Inc. (AKSCI)	J10034	http://www.aksci.com/item_detail.php?cat=J10034
Alfa Chemistry	AP79794755	https://reagents.alfa-chemistry.com/product/loratadine-cas-79794-75-5-16699.html
Angene	AGN-PC-0UFD74	http://www.angenechemical.com/productshow/AGN-PC-0UFD74.html
ApexBio Technology	A2960	http://www.apexbt.com/loratadine-22071.html
Ark Pharm	AK-88666	http://www.arkpharminc.com/products/79794-75-5.html
AstaTech, Inc.	34558	http://www.astatechinc.com/CPSResult.php?CRNO=35766
Aurum Pharmatech LLC	M-5196	http://www.Aurumpharmatech.com/Product/ProductDetails/M_5196
AvaChem Scientific	2987	http://www.avachem.com/productSearch.asp?2987
Avantor Inc	100573-700	https://us.vwr.com/store/catalog/product.jsp?catalog_number=100573-700
Axon MedChem	1299	https://www.axonmedchem.com/product/1299
BioChemPartner	BCP22338	http://www.biochempartner.com/79794-75-5-BCP22338
BioCrick	BCC1262	http://www.biocrick.com/Loratadine-BCC1262.html
BioSynth	Q-100833	https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-100833.html
BLD Pharm	BD22650	http://www.bldpharm.com/products/79794-75-5.html
BLD Pharm	BD341540	http://www.bldpharm.com/products/79794-75-5.html
BOC Sciences	1020719-57-6	https://www.bocsci.com/loratadine-d5-cas-1020719-57-6-item-472497.html
BOC Sciences	1398065-63-8	https://www.bocsci.com/loratadine-d5-ethyl-d5-cas-1398065-63-8-item-7891.html
Chem Scene	CS-0887	http://www.chemscene.com/79794-75-5.html
Chemenu	CM110558	http://www.chemenu.com/products/CM110558
ChemMol	30101835	http://www.chemmol.com/chemmol/30101835.html
ChemMol	44001626	http://www.chemmol.com/chemmol/44001626.html
ChemMol	49408235	http://www.chemmol.com/chemmol/49408235.html
ChemMol	97900024	http://www.chemmol.com/chemmol/97900024.html
ChemReagents	80006240	http://www.chemreagents.com/Product/Product.asp?ProductID=80006240
Chemspace	CSSB00000693942	https://chem-space.com/CSSB00000693942
Clearsynth	CS-O-01778	https://www.clearsynth.com/en/CSO01778.html
Clearsynth	CS-O-03616	http://www.clearsynth.com/en/CSO03616.html
Clearsynth	CS-O-07780	http://www.clearsynth.com/en/CSO07780.html
CSNpharm	CSN12956	https://www.csnpharm.com/products/loratadine.html
DC Chemicals	DC9104	http://www.dcchemicals.com/product_show-Loratadine.html
Enamine	Z1741979837	https://www.enaminestore.com/catalog/Z1741979837
eNovation Chemicals	D378653	https://www.enovationchem.com/ProductDetails.asp?ProductID=D378653
eNovation Chemicals	D488439	https://www.enovationchem.com/ProductDetails.asp?ProductID=D488439
Finetech	FT-0627976	http://www.finetechnology-ind.com/prod/detail/pub/79794-75-5.html
Glentham Life Sciences	GP7681	http://www.glentham.com/products/product/GP7681/
iChemical	EBD53298	http://www.ichemical.com/products/79794-75-5.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00188253	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00188253
LGC Standards	LGCAMP0257.00-02	https://www.lgcstandards.com/US/en/p/LGCAMP0257.00-02
LGC Standards	LGCFOR0257.00	https://www.lgcstandards.com/US/en/p/LGCFOR0257.00
LGC Standards	MM0257.00-0250	https://www.lgcstandards.com/US/en/p/MM0257.00-0250
Matrix Scientific	89794	https://www.matrixscientific.com/089794.html
mcule	MCULE-5073177964	https://mcule.com/MCULE-5073177964/
MedChem Express	HY-17043	https://www.medchemexpress.com/Loratadine.html
Molcore	CS15960	https://www.molcore.com/product/79794-75-5
Oakwood	214656	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=95655&ExtHyperLink=1
OChem	3802	http://www.ocheminc.com/index.php?act=psearch&pid=794L755
Selleck Chemicals	S1358	http://www.selleckchem.com/products/Loratadine.html
Sigma-Aldrich	1370270_USP	https://www.sigmaaldrich.com/catalog/product/usp/1370270?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	BP874_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/bp874?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	L9664_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/l9664?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PHR1376_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1376?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	Y0000603_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/y0000603?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S533555	http://www.smolecule.com/products/s533555
Synblock Inc	AB06849	http://www.synblock.com/product/79794-75-5.html
TCI (Tokyo Chemical Industry)	L0223	http://www.tcichemicals.com/eshop/en/us/commodity/L0223/index.html
THE BioTek	bt-273709	https://www.thebiotek.com/product/inhibitors/bt-273709
Tocris	1944	https://www.tocris.com/products/loratidine_1944
TripleBond	CL0028	http://www.triplebond-canada.com/prod/1411/
VladaChem	VL272222-1g	https://www.vladachem.com/product.php?products=79794-75-5
Yuhao Chemical	RT4149	http://www.chemyuhao.com/165739-83-3.html

PubMed

Title	Date	PubMed
Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine.	1999 Dec 15	10529725
Central nervous system effects of H1-receptor antagonists in the elderly.	1999 Feb	10071518
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study.	1999 Jan	10188144
Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups.	1999 Jun	10400480
Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years' duration.	1999 Sep	10507453
Antiallergic effects of H1-receptor antagonists.	2000	11291777
Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats.	2000 Dec 22	11134603
Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.	2000 Jan	10604956
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction.	2001	11243503
Desloratadine in the treatment of chronic idiopathic urticaria.	2001	11243502
Desloratadine activity in concurrent seasonal allergic rhinitis and asthma.	2001	11243501
Safety of antihistamines in children.	2001	11235817
Evaluation of a four-channel multiplexed electrospray triple quadrupole mass spectrometer for the simultaneous validation of LC/MS/MS methods in four different preclinical matrixes.	2001 Apr 15	11338587
Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma.	2001 Apr 20	11358228
Newer antihistamines.	2001 Apr 30	11331439
[A new antihistamine. Inhibiting inflammation in rhinorrhea and nasal congestion].	2001 Apr 5	11340914
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein.	2001 Aug	11454724
Applications of new liquid chromatography-tandem mass spectrometry technologies for drug development support.	2001 Aug 10	11554418
Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system.	2001 Dec	11770694
Antihistamines and serum adhesion molecule levels.	2001 Jun	11505807
High-dose loratadine exposure in a six-year-old child.	2001 Jun	11383659
Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.	2001 Mar	11240972
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow.	2001 Mar	11179434
Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine.	2001 May	11343039
Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus.	2001 May 11	11432448
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis.	2001 Nov	11703222
Effect of specific immunotherapy versus loratadine on serum adhesion molecules.	2001 Oct	11763722
Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin.	2001 Oct	11576078
Controlled clinical study of the efficacy of loratadine in Nigerian patients with allergic rhinitis.	2001 Sep	11721215
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine.	2002	11978146
Comparison of five new antihistamines (H1-receptor antagonists) in patients with allergic rhinitis using nasal provocation studies and skin tests.	2002 Apr	11906367
A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis.	2002 Jan	12002729
The effect of loratadine in exercise-induced asthma.	2002 Jan	11806881
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing.	2002 Jan 1	11813466
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.	2002 Jun	12063524
Med-psych drug-drug interactions update.	2002 Mar-Apr	11998586
Ventricular tachycardia following ingestion of a commonly used antihistamine.	2002 May 6	12056995

Patents

Sample Use Guides

In Vivo Use Guide

Adults and children 6 years and over: 1 tablet daily; not more than 1 tablet in 24 hours

Route of Administration: Oral

In Vitro Use Guide

dose-dependent inhibition of histamine release was observed at loratadine dose above 7 UM. In the rat basophilic leukemia cells (RBL-2H3) experimental system, inhibition by loratadine increased when the concentration of extracellular Ca2+ was reduced from 1.8 to 0.45 mM. Loratadine also inhibited the Mn2+ influx into these cells, thus reflecting the Ca2+ influx.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:00:54 GMT 2025` Edited by `admin` on `Mon Mar 31 18:00:54 GMT 2025`
Record UNII	7AJO3BO7QN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLARITIN-D COMPONENT LORATADINE

Preferred Name

English

LORATADINE

Official Name

English

SCH-29851

Code

English

Loratadine [WHO-DD]

Common Name

English

1-PIPERIDINECARBOXYLIC ACID, 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO(5,6)CYCLOHEPTA(1,2-B)PYRIDIN-11-YLIDENE)-, ETHYL ESTER

Common Name

English

LORATADINE [MART.]

Common Name

English

LORATADINE [USP MONOGRAPH]

Common Name

English

LORATADINE [EP MONOGRAPH]

Common Name

English

LORATADINE [HSDB]

Common Name

English

LORATADINE [MI]

Common Name

English

BAY76-2211

Code

English

LORATADINE [USP-RS]

Common Name

English

SCH 29851

Code

English

LORATADINE [USAN]

Common Name

English

ALAVERT

Brand Name

English

loratadine [INN]

Common Name

English

NSC-758628

Code

English

LORATADINE [ORANGE BOOK]

Common Name

English

LORATADINE [VANDF]

Common Name

English

LORATADINE [JAN]

Common Name

English

CLARITIN

Brand Name

English

LORATADINE [EP IMPURITY]

Common Name

English

Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

R06AX13